In ovarian mucinous tumors, cyclin dependent kinase inhibitor 2A (CDKN2A) and KRAS mutations represent the most common genetic alterations in both ovarian mucinous adenocarcinoma and their precursor lesions. The gene discussed is KRAS; the disease is ovarian mucinous neoplasm.